Smart Drug Conjugated Silica Nanoparticles for Controlled and Sustained Release

Wanxia Zhao

School of Chemical Engineering

A thesis submitted for the degree of

Master of Philosophy

The University of Adelaide

October 2015
Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University’s digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Signature: _________________________    Date: ___________________________
Acknowledgment

I would like to take this opportunity to thank all the people who helped and supported me during my two years Master of Philosophy study at the University of Adelaide. It is their impressive kindness and advices made this thesis possible.

First and foremost, I would like to express my deepest gratitude to my supervisors Associate Professors Sheng Dai and Jingxiu Bi for their valuable guidance, patience and encouragement in every stage of my study. Their effective suggestions, shrewd comments and vigorous academic observation have enlightened me not only in this thesis, but also in my future study and career.

I shall extend my thanks to Dr. Hu Zhang in our research group, who has given me generous helps and suggestions through my study. I would also like to thanks Dr. Xin Du, Mr. Xiaolin Cui, Mr. Bingyang Zhang as well as other research group members from School of Chemical Engineering, the University of Adelaide for their help and support on my experiments. They offer me not only useful discussions and suggestions, but also valuable friendships.

Last but not least, my greatest gratitude must go to my parents who provide me constant encouragement and endless love throughout my life.
Abstract

Drug delivery system (DDS) is crucial for modern cancer treatment. Traditional drug delivery process is to load drugs into various carriers via physical interactions, which always gives rise to the burst release and leakage of the loaded drugs. This thesis aims to develop a novel delivery platform with controlled and sustained drug release ability, where doxorubicin (DOX, a model anticancer drug) is conjugated to the surfaces of model carriers, silica nanoparticles (SNs), via different “smart” linkers. pH and glutathione (GSH) are utilized as the stimuli of these “smart” linkers to construct pH and intracellular microenvironment redox responsive drug-carrier conjugated delivery systems to selectively deliver drugs.

The pH regulated drug delivery system was developed to conjugate DOX to the surfaces of silica nanoparticles by acid responsive hydrazone bonds. The drug delivery system showed good stability under physiological pH of 7.4 to avoid premature drug leakage in blood circulation, and sustained release under acidic extracellular environment of cancer cells to effectively inhibit tumor growth. In vitro cytotoxicity study against Hela cells and HEK 293 cells indicated the drug delivery system revealed such a system could release more drugs in tumor cells than normal cells.

The intracellular microenvironment redox responsive drug delivery system was established by introducing dithiodibutyric acid (DTDB), which contained redox responsive disulfide bonds, to silica nanoparticle surfaces. In the absence of reducing
reagents of GSH or dithiothreitol (DTT), such a drug delivery system presented good stability to prevent drug leakage, but in the presence of GSH or DTT, the disulfide bonds could be effectively cleaved to release the preloaded drugs. The in vitro cytotoxicity study indicated this drug delivery system could be stable in blood circulation and effectively released the preloaded drugs inside cells after conjugation. Due to the different GSH levels in cancer cells and normal cells, intracellular microenvironment redox responsive system could be more toxic to cancer cells.

In summary, DOX-silica nanoparticles conjugates with pH regulated hydrazone bonds or intracellular microenvironment redox responsive disulfide bonds had the capability in controlled and sustained drug release, which could effectively eliminate drug leakage during the delivery course and release sufficient amount of drugs in tumors to inhibit their growth.
# Table of Contents

DECLARATION......................................................................................................................... I

ACKNOWLEDGMENT ................................................................................................................... II

ABSTRACT................................................................................................................................. III

Chapter 1 Introduction .............................................................................................................. 1

  1.1 Background ....................................................................................................................... 1
  1.2 Aims and objectives ........................................................................................................... 4
  1.3 Outline of the thesis .......................................................................................................... 5

References ............................................................................................................................... 6

Chapter 2 Literature Review .................................................................................................... 8

  2.1 The importance of drug delivery systems in cancer therapy ........................................... 8
  2.2 Traditional drug delivery systems using silica nanoparticles ........................................ 10
  2.3 Covalent conjugation of drugs to carriers by pH sensitive linkers ................................. 15
      2.3.1 Amide bonds ............................................................................................................... 16
      2.3.2 Hydrazine bond ......................................................................................................... 19
  2.4 Drug conjugation by intracellular microenvironment responsive linker ....................... 23
      2.4.1 Enzyme responsive drug delivery systems ............................................................... 24
      2.4.2 Redox responsive drug delivery systems ................................................................... 28
  2.5 Summary .......................................................................................................................... 31

References ............................................................................................................................... 32

Chapter 3 Doxorubicin conjugated silica nanoparticles: A pH regulated delivery
system for controlled and sustained drug release ................................................................. 38

  Abstract ................................................................................................................................. 42
  3.1 Introduction ....................................................................................................................... 43
  3.2 Materials and Methods ..................................................................................................... 45
      3.2.1 Materials .................................................................................................................. 45
Chapter 4 Intracellular microenvironment redox-responsive drug-conjugated silica nanoparticles for sustainable drug delivery ........................................... 76

Abstract ............................................................................................................. 80

4.1 Introduction ................................................................................................. 81

4.2 Materials and Methods ............................................................................... 83

4.2.1 Materials .................................................................................................. 83

4.2.2 Synthesis of monodisperse silica nanoparticles ........................................ 84

4.2.3 Synthesis of redox sensitive linker modified silica nanoparticles .......... 84

4.2.4 Drug conjugation and ex vivo drug release evaluation ......................... 85

4.2.5 Cytotoxicity ............................................................................................. 86

4.2.6 Fluorescent Dead/Live cell assays ...................................................... 87

4.2.7 Equipment ............................................................................................... 88
4.3 Results and Discussion ............................................................................................................. 88
  4.3.1 Preparation and characterization of SNs-S-S-DOX conjugates .............................. 88
  4.3.2 Ex vivo redox-responsive triggered cleavage of the SNs-S-S-DOX conjugates by DTT and GSH ................................................................. 91
  4.3.3 In vitro evaluation of cytotoxicity and cell uptake against HeLa cells and HEK 293 cells ......................................................................................... 93
  4.4 Conclusions ......................................................................................................................... 95

References .................................................................................................................................. 105

Supporting information ............................................................................................................. 108

Chapter 5 Conclusions and Recommendation ........................................................................ 110
  5.1 Conclusions ......................................................................................................................... 110
  5.2 Future recommendation .................................................................................................... 112